Co­herus and Ab­b­Vie set­tle Hu­mi­ra biosim­i­lar dis­pute af­ter Mark Cuban's Cost Plus Drugs an­nounce­ment

Biosim­i­lars play­er Co­herus Bio­sciences has patched things up with Ab­b­Vie af­ter the phar­ma said Co­herus vi­o­lat­ed its non-ex­clu­sive li­cense to com­mer­cial­ize Yusim­ry, a biosim­i­lar of …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER